<DOC>
	<DOCNO>NCT00467506</DOCNO>
	<brief_summary>Phase II clinical trial assess efficacy toxicity pretargeted radioimmunotherapy use anti-CEAxanti-DTPA bispecific antibody di-DTPA-131I peptide patient reccurrence medullary thyroid carcinoma ( abnormal calcitonin level biomarkers double time low 5 year )</brief_summary>
	<brief_title>Phase II Two-step Radioimmunotherapy Clinical Study Medullary Thyroid Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>18 75 year Karnofsky ≥ 70 % Histological diagnosis medullary thyroid carcinoma Calcitonin serum level Ê 100 pg/ml Calcitonin CEA double time £ 5 year Normal liver renal function Granulocytes ≥ 1500/mm3 platelet ≥ 150 000/mm3 No immunization Consent form sign</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Recurrence medullary thyroid carcinoma : abnormal calcitonin level biomarkers double time low 5 year initial surgery</keyword>
</DOC>